Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

2023-01-17

上市批准临床3期临床2期

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from

pruritus

, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST.

The event will highlight the launch of KORSUVA® (difelikefalin) injection and feature presentations during which healthcare providers will discuss the unmet medical need in

pruritus

associated with non-dialysis dependent

chronic kidney disease

atopic dermatitis

and

notalgia paresthetica

. The Company’s registrational Phase 2/3 program of oral difelikefalin in

notalgia paresthetica

patients with moderate-to-severe

pruritus

will also be discussed.

Presenters will include:

Christopher Posner, President and Chief Executive Officer, Cara Therapeutics

Joana Goncalves, M.D., Chief Medical Officer, Cara Therapeutics

Eric Vandal, Senior Vice President, Commercial, Cara Therapeutics

Joel Topf, M.D., FACP, Assistant Clinical Professor of Medicine at Oakland University William Beaumont School of Medicine, and Medical Director of St. Clair Nephrology Research

Jennifer Scherer, M.D., Assistant Professor of Palliative Care and Nephrology at the NYU Grossman School of Medicine, and Director of the Kidney CARES Program at NYU Langone Health

Raj Chovatiya, M.D., Ph.D., Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine, and Director of the Center for

Eczema

and

Itch

at Northwestern University

Shawn Kwatra, M.D., FAAD, Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine, and Director of the Johns Hopkins

Itch

Center

To register for the event, please click here.

A live webcast of the event will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the event.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from

pruritus

. The Company’s novel KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe

pruritus

associated with

chronic kidney disease

in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of

pruritus

in patients with non-dialysis dependent advanced

chronic kidney disease

and

atopic dermatitis

. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe

pruritus

in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。